Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Operating Leases (2021 - 2025)

Anaptysbio (ANAB) has disclosed Operating Leases for 5 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 14.74% year-over-year to $12.0 million, compared with a TTM value of $12.0 million through Dec 2025, down 14.74%, and an annual FY2025 reading of $12.0 million, down 14.74% over the prior year.
  • Operating Leases was $12.0 million for Q4 2025 at Anaptysbio, down from $14.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $20.2 million in Q2 2021 and bottomed at $12.0 million in Q4 2025.
  • Average Operating Leases over 5 years is $16.8 million, with a median of $16.9 million recorded in 2023.
  • The sharpest move saw Operating Leases changed 0.0% in 2023, then fell 19.89% in 2024.
  • Year by year, Operating Leases stood at $19.4 million in 2021, then decreased by 8.42% to $17.8 million in 2022, then fell by 9.97% to $16.0 million in 2023, then fell by 12.0% to $14.1 million in 2024, then dropped by 14.74% to $12.0 million in 2025.
  • Business Quant data shows Operating Leases for ANAB at $12.0 million in Q4 2025, $14.6 million in Q3 2025, and $15.1 million in Q2 2025.